Form 8-K - Current report:
SEC Accession No. 0001104659-25-020108
Filing Date
2025-03-04
Accepted
2025-03-04 11:29:49
Documents
17
Period of Report
2025-02-28
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 2.01: Completion of Acquisition or Disposition of Assets
Item 2.03: Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 FORM 8-K tm254408d1_8k.htm   iXBRL 8-K 59144
2 EXHIBIT 99.1 tm258076d1_ex99-1.htm EX-99.1 19232
3 EXHIBIT 99.2 tm258076d1_ex99-2.htm EX-99.2 17374
4 EXHIBIT 99.3 tm258076d1_ex99-3.htm EX-99.3 8399
5 EXHIBIT 99.4 tm258076d1_ex99-4.htm EX-99.4 6764
  Complete submission text file 0001104659-25-020108.txt   299693

Data Files

Seq Description Document Type Size
6 XBRL TAXONOMY EXTENSION SCHEMA acur-20250228.xsd EX-101.SCH 3021
7 XBRL TAXONOMY EXTENSION LABEL LINKBASE acur-20250228_lab.xml EX-101.LAB 34240
8 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE acur-20250228_pre.xml EX-101.PRE 22363
19 EXTRACTED XBRL INSTANCE DOCUMENT tm254408d1_8k_htm.xml XML 3580
Mailing Address 616 N. NORTH COURT, SUITE 120 . PALATINE IL 60067
Business Address 616 N. NORTH COURT, SUITE 120 PALATINE IL 60067 847-705-7709
ACURA PHARMACEUTICALS, INC (Filer) CIK: 0000786947 (see all company filings)

EIN.: 110853640 | State of Incorp.: NY | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-10113 | Film No.: 25702234
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)